Artemis Hospitals
Non-Hodgkin's lymphoma treatment cost in India typically runs from AUD $58 to AUD $144 for a specialist hematology consultation, while primary interventions like chemotherapy range between AUD $865 and AUD $3,172. Total expenses depend on the cancer stage, drug protocols, and the hospital tier. Australian patients usually save 60–80% compared to local private healthcare costs. Top medical hubs include Delhi, Mumbai, and Bengaluru.
Typical Non-Hodgkin's Lymphoma Treatment Costs in India
Bookimed Expert Insight: India offers exceptional value for complex hematology, with savings of up to 80% compared to Australia. Patients requiring advanced transplants should consider specialists like Dr. Rahul Bhargava at Fortis, who has performed over 1,000 transplants. For tailored pharmaceutical plans, Manipal Goa Hospital uses IBM Watson technology to select the most effective cancer treatments. Multidisciplinary care is standard at JCI-accredited centres like Artemis Hospitals.
| India | Thailand | Turkey | |
| Radiation therapy for colorectal cancer | from AUD $4,614 | from AUD $7,930 | from AUD $10,092 |
| Chemotherapy for breast cancer | from AUD $5,046 | from AUD $4,325 | from AUD $1,730 |
| Chemotherapy | from AUD $793 | from AUD $2,883 | from AUD $3,503 |
| Bone marrow transplantation | from AUD $21,626 | from AUD $72,087 | from AUD $51,903 |
| Autologous bone marrow transplantation | from AUD $15,859 | from AUD $57,670 | from AUD $45,415 |
No hidden fees – just official clinic prices. Pay at the clinic for Non-Hodgkin's lymphoma treatment and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Non-Hodgkin's lymphoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Non-Hodgkin's lymphoma treatment journey.
Dr Gaurav Kharya is a specialist in paediatric haematology and oncology who leads the bone marrow transplant team at Artemis Hospitals.
Professor Girish Badarkhe is a specialist haematology–oncologist at HCG Manavata Cancer Centre with extensive expertise in treating complex blood cancers.
Non-Hodgkin's lymphoma is highly curable in India, particularly aggressive subtypes like diffuse large B-cell lymphoma. Doctors use international R-CHOP protocols and CAR T-cell therapy. Major JCI-accredited hospitals in Bengaluru and Delhi report complete remission rates reaching 70%. These rates apply to standard first-line treatments.
Bookimed Expert Insight: Indian oncology centres often offer high-density diagnostic tech. This includes 4D radiotherapy and Alpha-knife radiosurgery, which isn't standard in every region. For example, HCG Manavata Cancer Centre has performed over 65,000 cancer surgeries. This high volume allows surgeons to manage complex relapsed cases. They use both autologous and allogeneic transplants with high precision.
Patient Consensus: Patients note that aggressive B-cell lymphomas often reach complete remission in India. They recommend confirming the exact subtype early. Treatments for mantle cell lymphoma focus on long-term management rather than a definitive cure.
Top Indian hospitals for Non-Hodgkin's lymphoma include Manipal Hospital, Apollo Hospital Indraprastha, and Artemis Hospitals. These centres hold JCI and NABH accreditations. These centres offer chemotherapy, immunotherapy, and bone marrow transplants. Specialist haematologists provide haploidentical stem cell transplants and CAR T-cell therapy for complex cases.
Bookimed Expert Insight: Many Australian patients look to major metros. However, HCG Manavata in Nashik represents a significant data standout. It is Maharashtra's first NABH-accredited cancer hospital and houses a US-FDA audited research institute. This combines high volume and international oversight. Patients therefore receive protocols validated to global clinical standards.
Patient Consensus: Patients note that confirming the specific lymphoma subtype before travel speeds up start times. Experience in India shows that government-funded hubs are affordable. However, private hospitals in Bengaluru and Delhi offer quicker admission for Australians.
India reports high survival rates for specific Non-Hodgkin lymphoma cases. Stage 4 classic Hodgkin lymphoma sees success in 87–90% of patients. Early diagnosis and cellular therapies in JCI-accredited centres significantly improve outcomes. These results often match global standards for aggressive subtypes.
Bookimed Expert Insight: Quality of outcome in India is often tied to facility volume and research. HCG Manavata Cancer Centre has performed 65,000+ surgeries and 65+ bone marrow transplants. Centres with US-FDA audited research units often provide more precise survival projections. Patients should focus on hospitals with dedicated paediatric or adult haematology-oncology wings. This can lead to better recovery prospects.
Patient Consensus: Patients emphasise getting a precise subtype diagnosis. They note that seeking second opinions at major Indian hospitals helps. This aligns local treatment plans with international standards. Many suggest using personal coordinators. These help manage the logistics of long-term care in Delhi or Bengaluru.
India provides immediate access to Non-Hodgkin's lymphoma treatments, including CAR T-cell therapy and allogeneic bone marrow transplants. JCI-accredited centres such as Artemis Hospitals and Manipal Hospitals offer complex diagnostics. They use PET-CT and IBM Watson for Oncology. This ensures high clinical accuracy. Patients also avoid the waiting lists sometimes found in public systems.
Bookimed Expert Insight: Many centres focus on chemotherapy. However, Indian clinics like Dr Rela Institute and HCG Manavata Cancer Centre lead in high-precision radiotherapy and bone marrow transplants. HCG Manavata is Maharashtra's first NABH-accredited cancer hospital. It completed over 65 bone marrow transplants in just 2.5 years. Patients seeking these specific, intensive procedures may find India's high-volume experience leads to smoother clinical pathways.
Patient Consensus: Patients note India is a strong choice when they need treatment to start quickly. They highlight the value of having personal coordinators, interpreters, and tailored meals. These are included in their stay.
Diagnosis in India follows a systematic path involving haematologist consultations, lymph node biopsies, and imaging. Specialists use immunophenotyping to identify specific lymphocyte markers. This provides precise classification of the lymphoma subtype. Major Indian medical centres often complete these assessments within a few days.
Bookimed Expert Insight: Indian diagnostic labs like those at Apollo Hospital Indraprastha are among the region's most modern. While some patients face delays elsewhere, leading private hubs often coordinate biopsy and IHC results simultaneously. This efficiency is vital. Accurate subtype identification directly dictates whether a patient needs chemotherapy or immunotherapy.
Patient Consensus: Patients note that initial symptoms like lumps are often mistaken for infections or tuberculosis. This is common in India. Confirming the diagnosis usually requires more than basic ultrasounds. It needs a definitive tissue biopsy and IHC testing.